Search

Your search keyword '"Jin, Jiankang"' showing total 138 results
Start Over Author "Jin, Jiankang"
138 results on '"Jin, Jiankang"'

1. Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression

Author

Wang, Ruiping, Song, Shumei, Qin, Jiangjiang, Yoshimura, Katsuhiro, Peng, Fuduan, Chu, Yanshuo, Li, Yuan, Fan, Yibo, Jin, Jiankang, Dang, Minghao, Dai, Enyu, Pei, Guangsheng, Han, Guangchun, Hao, Dapeng, Li, Yating, Chatterjee, Deyali, Harada, Kazuto, Pizzi, Melissa Pool, Scott, Ailing W., Tatlonghari, Ghia, Yan, Xinmiao, Xu, Zhiyuan, Hu, Can, Mo, Shaowei, Shanbhag, Namita, Lu, Yang, Sewastjanow-Silva, Matheus, Fouad Abdelhakeem, Ahmed Adel, Peng, Guang, Hanash, Samir M., Calin, George A., Yee, Cassian, Mazur, Pawel, Marsden, Autumn N., Futreal, Andrew, Wang, Zhenning, Cheng, Xiangdong, Ajani, Jaffer A., and Wang, Linghua

Published
2023
Full Text
View/download PDF

3. Three biomarkers (HER2, PD‐L1, and microsatellite status) in a large cohort of metastatic gastroesophageal adenocarcinomas: The MD Anderson Cancer Center experience.

Author

Sewastjanow‐Silva, Matheus, Kwiatkowski, Evan, Yamashita, Kohei, Abdelhakeem, Ahmed, Yoshimura, Katsuhiro, Vicentini, Ernesto R., Pizzi, Melissa P., Jin, Jiankang, Fan, Yibo, Zou, Gengyi, Wang, Lingzhi, Yin, Feng, Dhar, Shilpa S., Blum Murphy, Mariela, Mares, Jeannette E., Li, Jenny J., Gan, Qiong, Waters, Rebecca E., Rogers, Jane E., and Ajani, Jaffer A.

Subjects
EPIDERMAL growth factor, OVERALL survival, ESOPHAGEAL tumors, REGRESSION analysis, SURVIVAL analysis (Biometry)
Abstract

Human epidermal growth factor receptor‐2 (HER2), programmed death‐ligand 1 (PD‐L1), and microsatellite (MS) status are well‐established biomarkers in gastroesophageal adenocarcinomas (GEAs). However, it is unclear how the combination of these biomarkers is associated with clinicopathological factors and prognosis. This retrospective study included baseline metastatic GEA patients who were tested for all three biomarkers (HER2, PD‐L1, and MS status) at the MD Anderson Cancer Center between 2012 and 2022. Stratification was performed according to the combination of biomarker profiles: triple negative (TN), single positive (SP), and multiple positive (MP). Comparative analyses of clinicopathological factors and survival using combinations of biomarkers were performed. Among the 698 GEA patients analyzed, 251 (36.0%) were classified as TN, 334 (47.9%) as SP, and 113 (16.1%) as MP. The MP group showed a significant association with tumors located in the esophagus (p <.001), well to moderate differentiation (p <.001), and the absence of signet ring cells (p <.001). In the survival analysis, MP group had a significantly longer overall survival (OS) compared to the other groups (MP vs. TN, p <.001 and MP vs. SP, p <.001). Multivariate Cox regression analysis revealed that MP serves as an independent positive prognostic indicator for OS (hazard ratio = 0.63, p <.01). Our findings indicate that MP biomarkers are associated with a favorable prognosis in metastatic GEA. These results are reflective of clinical practice and offer valuable insights into how therapeutics and future biomarkers could influence therapy/prognosis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Correction to: LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma

Author

Xu, Yan, Li, Yuan, Jin, Jiankang, Han, Guangchun, Sun, Chengcao, Pizzi, Melissa Pool, Huo, Longfei, Scott, Ailing, Wang, Ying, Ma, Lang, Lee, Jeffrey H., Bhutani, Manoop S., Weston, Brian, Vellano, Christopher, Yang, Liuqing, Lin, Chunru, Kim, Youngsoo, MacLeod, A. Robert, Wang, Linghua, Wang, Zhenning, Song, Shumei, and Ajani, Jaffer A.

Published
2021
Full Text
View/download PDF

5. Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma

Author

Song, Shumei, Xu, Yan, Huo, Longfei, Zhao, Shuangtao, Wang, Ruiping, Li, Yuan, Scott, Ailing W., Pizzi, Melissa Pool, Wang, Ying, Fan, Yibo, Harada, Kazuto, Jin, Jiankang, Ma, Lang, Yao, Xiaodan, Shanbhag, Namita D., Gan, Qiong, Roy-Chowdhuri, Sinchita, Badgwell, Brian D., Wang, Zhenning, Wang, Linghua, and Ajani, Jaffer A.

Published
2021
Full Text
View/download PDF

6. Data from Galectin-3 Cooperates with CD47 to Suppress Phagocytosis and T-cell Immunity in Gastric Cancer Peritoneal Metastases

Author

Fan, Yibo, primary, Song, Shumei, primary, Li, Yuan, primary, Dhar, Shilpa S., primary, Jin, Jiankang, primary, Yoshimura, Katsuhiro, primary, Yao, Xiaodan, primary, Wang, Ruiping, primary, Scott, Ailing W., primary, Pizzi, Melissa Pool, primary, Wu, Jingjing, primary, Ma, Lang, primary, Calin, George A., primary, Hanash, Samir, primary, Wang, Linghua, primary, Curran, Michael, primary, and Ajani, Jaffer A., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Data from Galectin-3 Cooperates with CD47 to Suppress Phagocytosis and T-cell Immunity in Gastric Cancer Peritoneal Metastases

Author

Fan, Yibo, primary, Song, Shumei, primary, Li, Yuan, primary, Dhar, Shilpa S., primary, Jin, Jiankang, primary, Yoshimura, Katsuhiro, primary, Yao, Xiaodan, primary, Wang, Ruiping, primary, Scott, Ailing W., primary, Pizzi, Melissa Pool, primary, Wu, Jingjing, primary, Ma, Lang, primary, Calin, George A., primary, Hanash, Samir, primary, Wang, Linghua, primary, Curran, Michael, primary, and Ajani, Jaffer A., primary

Published
2023
Full Text
View/download PDF

11. LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma

Author

Xu, Yan, Li, Yuan, Jin, Jiankang, Han, Guangchun, Sun, Chengcao, Pizzi, Melissa Pool, Huo, Longfei, Scott, Ailing, Wang, Ying, Ma, Lang, Lee, Jeffrey H., Bhutani, Manoop S., Weston, Brian, Vellano, Christopher, Yang, Liuqing, Lin, Chunru, Kim, Youngsoo, MacLeod, A. Robert, Wang, Linghua, Wang, Zhenning, Song, Shumei, and Ajani, Jaffer A.

Published
2019
Full Text
View/download PDF

12. Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors

Author

Ajani, Jaffer A, Estrella, Jeannelyn S, Chen, Qiongrong, Correa, Arlene M, Ma, Lang, Scott, Ailing W, Jin, Jiankang, Liu, Bin, Xie, Min, Sudo, Kazuki, Shiozaki, Hironori, Badgwell, Brian, Weston, Brian, Lee, Jeffrey H, Bhutani, Manoop S, Onodera, Hisashi, Suzuki, Koyu, Suzuki, Akihiro, Ding, Sheng, Hofstetter, Wayne L, Johnson, Randy L, Bresalier, Robert S, and Song, Shumei

Published
2018
Full Text
View/download PDF

13. Abstract 4433: Galectin-3 synergizes with CD47 to suppress phagocytosis and T cell immunity in peritoneal metastases of gastric adenocarcinoma

Author

Fan, Yibo, primary, Song, Shumei, additional, Li, Yuan, additional, Dhar, Shilpa, additional, Jin, Jiankang, additional, Yao, Xiaodao, additional, Wang, Ruiping, additional, Wang, Ailing, additional, Pizzi, Melissa Pool, additional, Wu, Jingjing, additional, Yoshimura, Katsuhiro, additional, Ma, Lang, additional, Hanash, Samir, additional, Calin, George, additional, Wang, Linghua, additional, Curran, Michael, additional, and Ajani, Jaffer, additional

Published
2023
Full Text
View/download PDF

14. Abstract 1194: Evolution of immune and stromal cell states during the gastric cancer continuum

Author

Wang, Ruiping, primary, Song, Shumei, additional, Qin, Jiangjiang, additional, Yoshimura, Katsuhiro, additional, Peng, Fuduan, additional, Chu, Yanshuo, additional, Li, Yuan, additional, Fan, Yibo, additional, Jin, Jiankang, additional, Dang, Minghao, additional, Dai, Enyu, additional, Pei, Guangsheng, additional, Han, Guangchun, additional, Li, Yating, additional, Chatterjee, Deyali, additional, Pizzi, Melissa P., additional, Scott, Ailing W., additional, Tatlonghari, Ghia, additional, Yan, Xinmiao, additional, Sewastjanow, Matheus Da Silva, additional, Abdelhakeem, Ahmed Adel Fouad, additional, Mazur, Pawel K., additional, Cheng, Xiangdong, additional, Ajani, Jaffer A., additional, and Wang, Linghua, additional

Published
2023
Full Text
View/download PDF

22. Supplemental Figure 4 from The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer

Author

Song, Shumei, primary, Honjo, Soichiro, primary, Jin, Jiankang, primary, Chang, Shih-Shin, primary, Scott, Ailing W., primary, Chen, Qiongrong, primary, Kalhor, Neda, primary, Correa, Arlene M., primary, Hofstetter, Wayne L., primary, Albarracin, Constance T., primary, Wu, Tsung-Teh, primary, Johnson, Randy L., primary, Hung, Mien-Chie, primary, and Ajani, Jaffer A., primary

Published
2023
Full Text
View/download PDF

23. Supplemental Figure 1 from The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer

Author

Song, Shumei, primary, Honjo, Soichiro, primary, Jin, Jiankang, primary, Chang, Shih-Shin, primary, Scott, Ailing W., primary, Chen, Qiongrong, primary, Kalhor, Neda, primary, Correa, Arlene M., primary, Hofstetter, Wayne L., primary, Albarracin, Constance T., primary, Wu, Tsung-Teh, primary, Johnson, Randy L., primary, Hung, Mien-Chie, primary, and Ajani, Jaffer A., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 4 from YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer – Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer

Author

Li, Fan, primary, Xu, Yan, primary, Liu, Bovey, primary, Singh, Pankaj Kumar, primary, Zhao, Wei, primary, Jin, Jiankang, primary, Han, Guangchun, primary, Scott, Ailing W., primary, Dong, Xiaochuan, primary, Huo, Longfei, primary, Ma, Lang, primary, Pizzi, Melissa Pool, primary, Wang, Ying, primary, Li, Yuan, primary, Harada, Kazuto, primary, Xie, Min, primary, Skinner, Heath D., primary, Ding, Sheng, primary, Wang, Linghua, primary, Krishnan, Sunil, primary, Johnson, Randy L., primary, Song, Shumei, primary, and Ajani, Jaffer A., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 2 from YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer – Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer

Author

Li, Fan, primary, Xu, Yan, primary, Liu, Bovey, primary, Singh, Pankaj Kumar, primary, Zhao, Wei, primary, Jin, Jiankang, primary, Han, Guangchun, primary, Scott, Ailing W., primary, Dong, Xiaochuan, primary, Huo, Longfei, primary, Ma, Lang, primary, Pizzi, Melissa Pool, primary, Wang, Ying, primary, Li, Yuan, primary, Harada, Kazuto, primary, Xie, Min, primary, Skinner, Heath D., primary, Ding, Sheng, primary, Wang, Linghua, primary, Krishnan, Sunil, primary, Johnson, Randy L., primary, Song, Shumei, primary, and Ajani, Jaffer A., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Data from YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer – Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer

Author

Li, Fan, primary, Xu, Yan, primary, Liu, Bovey, primary, Singh, Pankaj Kumar, primary, Zhao, Wei, primary, Jin, Jiankang, primary, Han, Guangchun, primary, Scott, Ailing W., primary, Dong, Xiaochuan, primary, Huo, Longfei, primary, Ma, Lang, primary, Pizzi, Melissa Pool, primary, Wang, Ying, primary, Li, Yuan, primary, Harada, Kazuto, primary, Xie, Min, primary, Skinner, Heath D., primary, Ding, Sheng, primary, Wang, Linghua, primary, Krishnan, Sunil, primary, Johnson, Randy L., primary, Song, Shumei, primary, and Ajani, Jaffer A., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 1 from YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer – Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer

Author

Li, Fan, primary, Xu, Yan, primary, Liu, Bovey, primary, Singh, Pankaj Kumar, primary, Zhao, Wei, primary, Jin, Jiankang, primary, Han, Guangchun, primary, Scott, Ailing W., primary, Dong, Xiaochuan, primary, Huo, Longfei, primary, Ma, Lang, primary, Pizzi, Melissa Pool, primary, Wang, Ying, primary, Li, Yuan, primary, Harada, Kazuto, primary, Xie, Min, primary, Skinner, Heath D., primary, Ding, Sheng, primary, Wang, Linghua, primary, Krishnan, Sunil, primary, Johnson, Randy L., primary, Song, Shumei, primary, and Ajani, Jaffer A., primary

Published
2023
Full Text
View/download PDF

28. Supplemental Figure 3 from The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer

Author

Song, Shumei, primary, Honjo, Soichiro, primary, Jin, Jiankang, primary, Chang, Shih-Shin, primary, Scott, Ailing W., primary, Chen, Qiongrong, primary, Kalhor, Neda, primary, Correa, Arlene M., primary, Hofstetter, Wayne L., primary, Albarracin, Constance T., primary, Wu, Tsung-Teh, primary, Johnson, Randy L., primary, Hung, Mien-Chie, primary, and Ajani, Jaffer A., primary

Published
2023
Full Text
View/download PDF

29. A new intronic quantitative PCR method led to the discovery of transformation from human ascites to murine malignancy in a mouse model

Author

Jin, Jiankang, primary, Huo, Longfei, additional, Fan, Yibo, additional, Wang, Ruiping, additional, Scott, Ailing W., additional, Pizzi, Melissa Pool, additional, Yao, Xiaodan, additional, Shao, Shan, additional, Ma, Lang, additional, Da Silva, Matheus S., additional, Yamashita, Kohei, additional, Yoshimura, Katsuhiro, additional, Zhang, Boyu, additional, Wu, Jingjing, additional, Wang, Linghua, additional, Song, Shumei, additional, and Ajani, Jaffer A., additional

Published
2023
Full Text
View/download PDF

30. Additional file 2 of GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma

Author

Li, Yuan, Fan, Yibo, Xu, Jinbang, Huo, Longfei, Scott, Ailing W., Jin, Jiankang, Yang, Boxuan, Shao, Shan, Ma, Lang, Wang, Ying, Yao, Xiaodan, Pool Pizzi, Melissa, Sewastjanow Da Silva, Matheus, Zhang, Guoliang, Zhuo, Lijuan, Cho, Eun Jeong, Dalby, Kevin N., Shanbhag, Namita D., Wang, Zhenning, Li, Wenliang, Song, Shumei, and Ajani, Jaffer A.

Abstract

Addiitional file 2: Supplementary Figure1. GRK3 expression in PDX tumors of GAC and paired primary tumor and PC. A. Diagram demonstrates the several patients’ PC cells (malignant ascites cells) into nude mice to generate PDXs (left). Western blot of GRK3 expression of Primary and ascites from PDX tumor generated from GAC patient (right). B. Representative co-immunofluorescent staining images of GRK3 and SOX9 expression on more PC specimen. Scale bars, 25µm. C. Representative co-immunofluorescent staining images of GRK3 and SOX9 expression on paired human primary tumor and PC samples. Scale bars, 25µm. Supplementary Figure 2. Overexpression of GRK3 in GAC cells increased malignant behaviors of GAC. A. Cell viability assay (MTS) was performed in MKN45-GRK3 and MKN45-GFP control cells. Fold increases of cell growth in day 6 and day 8 in media with the indicated FBS % was plotted on y-axis. **P

Published
2022
Full Text
View/download PDF

31. Additional file 1 of GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma

Author

Li, Yuan, Fan, Yibo, Xu, Jinbang, Huo, Longfei, Scott, Ailing W., Jin, Jiankang, Yang, Boxuan, Shao, Shan, Ma, Lang, Wang, Ying, Yao, Xiaodan, Pool Pizzi, Melissa, Sewastjanow Da Silva, Matheus, Zhang, Guoliang, Zhuo, Lijuan, Cho, Eun Jeong, Dalby, Kevin N., Shanbhag, Namita D., Wang, Zhenning, Li, Wenliang, Song, Shumei, and Ajani, Jaffer A.

Abstract

Additional file 1: Supplementary Table 1. Designed guide RNA for GRK3 or YAP1knock-down. Supplementary Table 2. Primer sequences used in this study. Supplementary Table 3. Expression of GRK3 with patients’ characteristics. Supplementary Table 4. Univariate and Multivariate analysis of GRK3 in GAC patients. Supplementary Table 5. The correlation between GRK3 and YAP1 expression in GAC.

Published
2022
Full Text
View/download PDF

32. Additional file 1 of Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma

Author

Song, Shumei, Xu, Yan, Huo, Longfei, Zhao, Shuangtao, Wang, Ruiping, Li, Yuan, Scott, Ailing W., Pizzi, Melissa Pool, Wang, Ying, Fan, Yibo, Harada, Kazuto, Jin, Jiankang, Ma, Lang, Yao, Xiaodan, Shanbhag, Namita D., Gan, Qiong, Roy-Chowdhuri, Sinchita, Badgwell, Brian D., Wang, Zhenning, Wang, Linghua, and Ajani, Jaffer A.

Abstract

Additional file 1. Supplemental Materias & Methods.

Published
2021
Full Text
View/download PDF

33. Additional file 3 of Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma

Author

Song, Shumei, Xu, Yan, Huo, Longfei, Zhao, Shuangtao, Wang, Ruiping, Li, Yuan, Scott, Ailing W., Pizzi, Melissa Pool, Wang, Ying, Fan, Yibo, Harada, Kazuto, Jin, Jiankang, Ma, Lang, Yao, Xiaodan, Shanbhag, Namita D., Gan, Qiong, Roy-Chowdhuri, Sinchita, Badgwell, Brian D., Wang, Zhenning, Wang, Linghua, and Ajani, Jaffer A.

Abstract

Additional file 3: Supplemental Table 1. Patients’ characteristics.

Published
2021
Full Text
View/download PDF

34. Additional file 2 of Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma

Author

Song, Shumei, Xu, Yan, Huo, Longfei, Zhao, Shuangtao, Wang, Ruiping, Li, Yuan, Scott, Ailing W., Pizzi, Melissa Pool, Wang, Ying, Fan, Yibo, Harada, Kazuto, Jin, Jiankang, Ma, Lang, Yao, Xiaodan, Shanbhag, Namita D., Gan, Qiong, Roy-Chowdhuri, Sinchita, Badgwell, Brian D., Wang, Zhenning, Wang, Linghua, and Ajani, Jaffer A.

Abstract

Additional file 2: Supplemental Fig. 1. Genetic alteration of three donor PC cells and cell lines. A. Whole-exome sequencing was performed in three donor PC cells IP-013 (GA0518), IP-107-02 (GA0804) and IP-116 (GA0825) directly from patients according to the Materials and Methods. Mutations in three donor PC cells were analyzed by a bioinformatician (S.Z.). B&C. Karyotyping analyses of GA0518 (B) and Snu-1 (C) were performed by the Cytogenetics and Cell Authentication Core at MD Anderson as described in Materials and Methods. Abnormal chromosomal changes were observed in GA0518 (B) and Snu-1 (C). Red arrows indicate some of the chromosomal changes in each cell lines. Supplemental Fig. 2. Expression of CSC markers in the corresponding donor PC cell samples. Expression of several notable CSC markers (YAP1, EpCAM, ALDH1, and SOX9) in the corresponding donor PC cell samples (IP-013, IP-107-2, and IP-116) was determined by immunofluorescence staining as described in Materials and Methods. Supplemental Fig. 3. Expression of CD44, CD133, and EpCAM was evaluated by flow cytometry in the three new cell lines. Supplemental Fig. 4. Activation of stemness and oncogenic markers in three corresponding donor PC cells by CyTOF. CyTOF was performed in the donor PC cell samples IP-013, IP-107-2, and IP-116 according to the Materials and Methods. Activation of CSC markers (CD44 and ALDH1) and oncogenic pathways such as pS6, p-AKT, and mTOR was analyzed and identified by bioinformatician (R.W). Supplemental Fig. 5. Representative BLI images for GA0804 PDO model A. Representative BLI images from Day 1 to Day 36 in a GA0804 PDO mouse without PC metastasis; B. Representative BLI images in GA0804 PDO mouse with PC metastasis from Day 1 to Day 36. Supplemental Fig. 6. Representative BLI images for GA0825 and MKN45 PDO models. A. Representative BLI images from Day 1 to Day 27 in two PDO mouse models of GA0825 with no PC. B. Representative BLI images from Day 9 to Day 26 in two PDO mouse models of commercial GAC cell line MKN45 with no PC. Supplemental Fig. 7. IC50 of three new cell lines on chemo and target inhibitors. The cell line GA0518 (A), GA0804 (B), and GA0825 (C) were seeded onto 96-well plates with 3000 cells/well. After overnight incubation, cells were treated with the indicated doses of two chemo-5-FU and Docetaxel; and two target inhibitors- Erlotinib and RAD001 for 6 days and then CellTiter96 Aqueous one solution was added to each well (20ul to 100ul culture media) followed by 2 h incubation at 37 °C and absorbance reading at OD 490. GraphPad Prism7 was used for IC50 analysis by following the instruction from GraphPad.com ( https://www.graphpad.com/support/faq/how-to-determine-an-icsub50sub/ ).

Published
2021
Full Text
View/download PDF

35. Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma

Author

Song, Shumei, primary, Chen, Qiongrong, additional, Li, Yuan, additional, Lei, Guang, additional, Scott, Ailing, additional, Huo, Longfei, additional, Li, Cordelia Y, additional, Estrella, Jeannelyn Santiano, additional, Correa, Arlene, additional, Pizzi, Melissa Pool, additional, Ma, Lang, additional, Jin, Jiankang, additional, Liu, Bin, additional, Wang, Ying, additional, Xiao, Lianchun, additional, Hofstetter, Wayne L, additional, Lee, Jeffrey H, additional, Weston, Brian, additional, Bhutani, Manoop, additional, Shanbhag, Namita, additional, Johnson, Randy L, additional, Gan, Boyi, additional, Wei, Shaozhong, additional, and Ajani, Jaffer A, additional

Published
2021
Full Text
View/download PDF

36. Multifunctional Tumor-Targeted Nanoparticles for Lung Cancer

Author

Kuroda, Shinji, primary, Yokoyama, Tomohisa, additional, Tam, Justina, additional, Scott, Ailing, additional, Ma, Li, additional, Shanker, Manish, additional, Jin, Jiankang, additional, Goerlich, Corbin, additional, Willcutts, David, additional, Roth, Jack, additional, Sokolov, Konstantin, additional, Johnston, Keith, additional, and Ramesha, Rajagopal, additional

Published
2012
Full Text
View/download PDF

38. LncRNA PVT1 Is a Poor Prognosticator and Can Be Targeted by PVT1 Antisense Oligos in Gastric Adenocarcinoma

Author

Li, Yuan, primary, Song, Shumei, additional, Pizzi, Melissa Pool, additional, Han, Guangchun, additional, Scott, Ailing W., additional, Jin, Jiankang, additional, Xu, Yan, additional, Wang, Ying, additional, Huo, Longfei, additional, Ma, Lang, additional, Vellano, Christopher, additional, Luo, Xiaolin, additional, MacLeod, Robert, additional, Wang, Linghua, additional, Wang, Zhenning, additional, and Ajani, Jaffer A., additional

Published
2020
Full Text
View/download PDF

39. YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition

Author

Ajani, Jaffer A, primary, Xu, Yan, additional, Huo, Longfei, additional, Wang, Ruiping, additional, Li, Yuan, additional, Wang, Ying, additional, Pizzi, Melissa Pool, additional, Scott, Ailing, additional, Harada, Kazuto, additional, Ma, Lang, additional, Yao, Xiaodan, additional, Jin, Jiankang, additional, Zhao, Wei, additional, Dong, Xiaochuan, additional, Badgwell, Brian D, additional, Shanbhag, Namita, additional, Tatlonghari, Ghia, additional, Estrella, Jeannelyn Santiano, additional, Roy-Chowdhuri, Sinchita, additional, Kobayashi, Makoto, additional, Vykoukal, Jody V, additional, Hanash, Samir M, additional, Calin, George Adrian, additional, Peng, Guang, additional, Lee, Ju-Seog, additional, Johnson, Randy L, additional, Wang, Zhenning, additional, Wang, Linghua, additional, and Song, Shumei, additional

Published
2020
Full Text
View/download PDF

40. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma

Author

Song, Shumei, primary, Li, Yuan, additional, Xu, Yan, additional, Ma, Lang, additional, Pool Pizzi, Melissa, additional, Jin, Jiankang, additional, Scott, Ailing W, additional, Huo, Longfei, additional, Wang, Ying, additional, Lee, Jeffrey H., additional, Bhutani, Manoop S., additional, Weston, Brian, additional, Shanbhag, Namita D, additional, Johnson, Randy L., additional, and Ajani, Jaffer A., additional

Published
2020
Full Text
View/download PDF

43. YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer – Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer

Author

Li, Fan, primary, Xu, Yan, additional, Liu, Bovey, additional, Singh, Pankaj Kumar, additional, Zhao, Wei, additional, Jin, Jiankang, additional, Han, Guangchun, additional, Scott, Ailing W., additional, Dong, Xiaochuan, additional, Huo, Longfei, additional, Ma, Lang, additional, Pizzi, Melissa Pool, additional, Wang, Ying, additional, Li, Yuan, additional, Harada, Kazuto, additional, Xie, Min, additional, Skinner, Heath D., additional, Ding, Sheng, additional, Wang, Linghua, additional, Krishnan, Sunil, additional, Johnson, Randy L., additional, Song, Shumei, additional, and Ajani, Jaffer A., additional

Published
2019
Full Text
View/download PDF

44. Abstract 1071: Overexpression of SHH and GLI1 contributes to poor prognosis and peritoneal metastases in gastric adenocarcinoma

Author

Xu, Yan, primary, Li, Yuan, additional, Liu, Bovey, additional, Pizzi, Melissa Pool, additional, Song, Yongxi, additional, Harada, Kazuto, additional, Scott, Ailing, additional, Ma, Lang, additional, Jin, Jiankang, additional, Dong, Xiaochuan, additional, Wang, Ying, additional, Badgwell, Brian D., additional, Estrella, Jeannelyn S., additional, Sinchita, Roy-Chowdhuri, additional, Amlashi, Fatemeh G., additional, Wang, Zhenning, additional, Song, Shumei, additional, and Ajani, Jaffer A., additional

Published
2018
Full Text
View/download PDF

45. Abstract 288: Genomic profiling of metastatic gastric adenocarcinoma

Author

Harada, Kazuto, primary, Song, Shumei, additional, Xu, Yan, additional, Bagewell, Brain D., additional, Pizzi, Melissa P., additional, Jin, Jiankang, additional, Wang, Ying, additional, Scott, Ailing W., additional, Ma, Lang, additional, Amlashi, Fatemeh G., additional, Kobayashi, Makoto, additional, Vykoukal, Jody V., additional, Ivan, Cristina, additional, Estrella, Jeannelyn S., additional, Chowdhuri, Sinchita R., additional, Calin, George A., additional, Hanash, Samir, additional, Lee, Ju-Seog, additional, Liu, Bin, additional, and Ajani, Jaffer A., additional

Published
2018
Full Text
View/download PDF

47. YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition

Author

Ajani, Jaffer A, Xu, Yan, Huo, Longfei, Wang, Ruiping, Li, Yuan, Wang, Ying, Pizzi, Melissa Pool, Scott, Ailing, Harada, Kazuto, Ma, Lang, Yao, Xiaodan, Jin, Jiankang, Zhao, Wei, Dong, Xiaochuan, Badgwell, Brian D, Shanbhag, Namita, Tatlonghari, Ghia, Estrella, Jeannelyn Santiano, Roy-Chowdhuri, Sinchita, Kobayashi, Makoto, Vykoukal, Jody V, Hanash, Samir M, Calin, George Adrian, Peng, Guang, Lee, Ju-Seog, Johnson, Randy L, Wang, Zhenning, Wang, Linghua, and Song, Shumei

Abstract

ObjectivePeritoneal carcinomatosis (PC; malignant ascites or implants) occurs in approximately 45% of advanced gastric adenocarcinoma (GAC) patients and associated with a poor survival. The molecular events leading to PC are unknown. The yes-associated protein 1 (YAP1) oncogene has emerged in many tumour types, but its clinical significance in PC is unclear. Here, we investigated the role of YAP1 in PC and its potential as a therapeutic target.MethodsPatient-derived PC cells, patient-derived xenograft (PDX) and patient-derived orthotopic (PDO) models were used to study the function of YAP1 in vitro and in vivo. Immunofluorescence and immunohistochemical staining, RNA sequencing (RNA-Seq) and single-cell RNA-Seq (sc-RNA-Seq) were used to elucidate the expression of YAP1 and PC cell heterogeneity. LentiCRISPR/Cas9 knockout of YAP1 and a YAP1 inhibitor were used to dissect its role in PC metastases.ResultsYAP1 was highly upregulated in PC tumour cells, conferred cancer stem cell (CSC) properties and appeared to be a metastatic driver. Dual staining of YAP1/EpCAM and sc-RNA-Seq revealed that PC tumour cells were highly heterogeneous, YAP1highPC cells had CSC-like properties and easily formed PDX/PDO tumours but also formed PC in mice, while genetic knockout YAP1 significantly slowed tumour growth and eliminated PC in PDO model. Additionally, pharmacologic inhibition of YAP1 specifically reduced CSC-like properties and suppressed tumour growth in YAP1highPC cells especially in combination with cytotoxics in vivo PDX model.ConclusionsYAP1 is essential for PC that is attenuated by YAP1 inhibition. Our data provide a strong rationale to target YAP1 in clinic for GAC patients with PC.

Published
2021
Full Text
View/download PDF

48. Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors

Author

Ajani, Jaffer A, primary, Estrella, Jeannelyn S, additional, Chen, Qiongrong, additional, Correa, Arlene M, additional, Ma, Lang, additional, Scott, Ailing W, additional, Jin, Jiankang, additional, Liu, Bin, additional, Xie, Min, additional, Sudo, Kazuki, additional, Shiozaki, Hironori, additional, Badgwell, Brian, additional, Weston, Brian, additional, Lee, Jeffrey H, additional, Bhutani, Manoop S, additional, Onodera, Hisashi, additional, Suzuki, Koyu, additional, Suzuki, Akihiro, additional, Ding, Sheng, additional, Hofstetter, Wayne L, additional, Johnson, Randy L, additional, Bresalier, Robert S, additional, and Song, Shumei, additional

Published
2017
Full Text
View/download PDF

49. Abstract 5862: YAP1 mediated CDK6 activation confers radiation resistance in esophageal cancer: rationale for the combination of YAP1 and CDK4/6 inhibitors in EC

Author

Li, Fan, primary, Dong, Xiaoquan, additional, Zhu, Haitao, additional, Scott, Ailing W., additional, Ma, Lang, additional, Jin, Jiankang, additional, Estrella, Jeannelyn Santiano, additional, Skinner, Heath, additional, Johnson, Randy L., additional, Song, Shumei, additional, and Ajani, Jaffer A., additional

Published
2017
Full Text
View/download PDF

50. Tumor Suppressor Gene-Based Nanotherapy: From Test Tube to the Clinic

Author

Shanker, Manish, Jin, Jiankang, Branch, Cynthia D., Miyamoto, Shinya, Grimm, Elizabeth A., Roth, Jack A., and Ramesh, Rajagopal

Subjects
Article Subject
Abstract

Cancer is a major health problem in the world. Advances made in cancer therapy have improved the survival of patients in certain types of cancer. However, the overall five-year survival has not significantly improved in the majority of cancer types. Major challenges encountered in having effective cancer therapy are development of drug resistance by the tumor cells, nonspecific cytotoxicity, and inability to affect metastatic tumors by the chemodrugs. Overcoming these challenges requires development and testing of novel therapies. One attractive cancer therapeutic approach is cancer gene therapy. Several laboratories including the authors' laboratory have been investigating nonviral formulations for delivering therapeutic genes as a mode for effective cancer therapy. In this paper the authors will summarize their experience in the development and testing of a cationic lipid-based nanocarrier formulation and the results from their preclinical studies leading to a Phase I clinical trial for nonsmall cell lung cancer. Their nanocarrier formulation containing therapeutic genes such as tumor suppressor genes when administered intravenously effectively controls metastatic tumor growth. Additional Phase I clinical trials based on the results of their nanocarrier formulation have been initiated or proposed for treatment of cancer of the breast, ovary, pancreas, and metastatic melanoma, and will be discussed.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results